2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 656

Breach of B Cell Tolerance in New Zealand Black Chromosome 1 Congenic Mice
Abstract Number: 2871

Break of Anergy in Human Autoreactive B Cells By T Helper Signals Restores B Cell Receptor Signaling Capacity and Is Dependent on Upregulation of CD45 Phosphatase Activity-a Possible Novel Mechanism of Breech of B Cell Tolerance in Rheumatic Diseases
Abstract Number: 659

Breakdown of Tolerance at the Tissue Level in Systemic Autoimmunity: Role of Tissue-Resident Dendritic Cells
Abstract Number: 1333

Bridging the Social Support Needs Gap for African American Women with Systemic Lupus Erythematosus through the Chronic Disease Self-Management Program
Abstract Number: 1728

Bromodomain Inhibitor JQ1 Modulates Collagen Processing and Ameliorates Bleomycin Induced Dermal Fibrosis in Mice
Abstract Number: 433

Bronchiectasis: A Model for Chronic Bacterial Infection Inducing Autoimmunity in Rheumatoid Arthritis
Abstract Number: 2752

Budd-Chiari Syndrome Due to Behçet’s Syndrome: Some Patients Present without Liver Related Symptoms and Have a Better Outcome
Abstract Number: 2125

Burden of Illness in Refractory Gouty Arthritis: A One-Year Prospective Multinational, Observational Study
Abstract Number: 938

C1q Is Mandatory for Disease Development in Experimental Arthritis and Expression of Its Receptors Correlates with Disease Activity in Patients
Abstract Number: 2798

C5orf30 a Novel Regulator of Inflammation and Tissue Damage in Rheumatoid Arthritis
Abstract Number: 1462

Cadherin-11 mRNA Expression in the Peripheral Blood of Rheumatoid Arthritis Patients As a Marker of Active Polyarthritis
Abstract Number: 528

Calcium-Calcineurin-NFAT Signaling Pathway Regulates AQP5 Expression in Primary Salivary Gland Acinar Cells
Abstract Number: 2988

Calgranulin Levels Are Elevated in Spondyloarthritis and Reflect the Presence of Acute Microscopic Gut Inflammation
Abstract Number: 2926

Calprotectin Serum Levels Reflect Residual Inflammatory Activity in Patients with Rheumatoid Arthritis and Psoriatic Arthritis on Clinical Remission or Low Disease Activity Undergoing TNF-Antagonists Therapy
Abstract Number: 2846

CaMK4 Inhibition Ameliorates the Development of Th17 Driven Inflammatory Diseases By Preventing Recruitment of IL-17 Producing Cells to Target Organs

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].